Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 17 May 2021 – On 7…
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 17 May 2021 – On 7…
UPPSALA, SWEDEN – LIDDS Annual General Meeting (AGM) was held on May 17, 2021….
Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks…
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:…
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a…
Multi-center Retrospective Study Demonstrates Statistically Significant Reduction in Signs and Symptoms of Dry Eye Disease…
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS17 MAY 2021 at 16.00 EEST …
THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of…
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from…
Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to…
DURHAM, N.C., May 17, 2021 (GLOBE NEWSWIRE) — Senior management of Bioventus Inc. (Nasdaq: BVS)…
Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic…
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader…
– Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property…
The partnership brings together one of the world’s premier microscopy vendors and Akoya’s high-parameter CODEX®…
JANUARY – MARCH 2021 Net sales amounted to MSEK 0.6 (0.0) Operating expenses amounted to…
BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a…
ORION CORPORATION PRESS RELEASE 17 MAY 2021 at 15.00 EEST Orion Animal Health’s Bonqat® (pregabalin)…
Cambridge, MA, May 17, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial…
Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and…